Captrust Financial Advisors Has $137.07 Million Stock Holdings in Amgen Inc. $AMGN

Captrust Financial Advisors boosted its stake in Amgen Inc. (NASDAQ:AMGN) by 5.9% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 485,703 shares of the medical research company’s stock after buying an additional 27,233 shares during the quarter. Captrust Financial Advisors owned approximately 0.09% of Amgen worth $137,065,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of AMGN. Laurel Wealth Advisors LLC increased its stake in shares of Amgen by 27,765.8% in the second quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock worth $1,870,880,000 after acquiring an additional 6,676,575 shares during the last quarter. Norges Bank acquired a new stake in Amgen during the second quarter valued at $1,663,726,000. Capital World Investors grew its stake in Amgen by 11.5% in the third quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock valued at $5,303,578,000 after purchasing an additional 1,935,876 shares in the last quarter. National Bank of Canada FI grew its stake in Amgen by 237.7% in the third quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock valued at $346,076,000 after purchasing an additional 863,216 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in Amgen by 1.6% in the 2nd quarter. Vanguard Group Inc. now owns 53,711,570 shares of the medical research company’s stock worth $14,996,807,000 after purchasing an additional 841,117 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on AMGN. Barclays started coverage on Amgen in a research note on Friday, February 20th. They set an “equal weight” rating and a $350.00 price target for the company. Piper Sandler increased their price objective on Amgen from $381.00 to $432.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Morgan Stanley raised their price objective on shares of Amgen from $304.00 to $309.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 4th. Erste Group Bank upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research note on Friday, December 5th. Finally, Royal Bank Of Canada increased their price target on shares of Amgen from $335.00 to $360.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $354.00.

Amgen Stock Performance

Shares of NASDAQ AMGN opened at $361.13 on Wednesday. The business’s 50-day simple moving average is $359.26 and its 200-day simple moving average is $326.77. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $391.29. The firm has a market cap of $194.67 billion, a price-to-earnings ratio of 25.38, a P/E/G ratio of 3.63 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping the consensus estimate of $4.76 by $0.53. The firm had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same period in the previous year, the company earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Friday, May 15th. Amgen’s payout ratio is presently 70.84%.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported stronger-than-expected results and raised FY guidance, supporting fundamentals and cash flow — a key reason some investors remain constructive. MarketBeat Earnings & Guidance
• Positive Sentiment: Analysts lifted Amgen’s fair-value estimate on growing confidence in execution and the MariTide obesity program, which boosts upside expectations if clinical/exclusivity risks are managed. Yahoo: Narrative Shifting
• Positive Sentiment: Large investor interest: Ken Fisher’s firm increased its Amgen stake, a vote of confidence from a prominent institutional investor. Yahoo: Ken Fisher Doubles Position
• Neutral Sentiment: Amgen is being watched by retail and professional traders (trending coverage), which can amplify moves but doesn’t by itself change fundamentals. Zacks: Trending Stock
• Neutral Sentiment: Reported short-interest data in recent feeds appears inconsistent/zeroed out and is not signaling a clear squeeze or covering dynamic at this time.
• Neutral Sentiment: Amgen’s shares were reported to outperform many peers on a relative-basis despite the intraday decline, indicating sector/stock-specific flows rather than a company-specific collapse. MarketWatch: Outperforms Peers
• Negative Sentiment: Amgen (with peers) is reportedly joining a drug-discount initiative (TrumpRx), which could pressure pricing and margins for certain products if discounts are material. Benzinga: TrumpRx Participation
• Negative Sentiment: Analyst upgrades and MariTide optimism are tempered by exclusivity and long-term earnings debate — unresolved regulatory/IP questions could cap upside until clearer trial and exclusivity outcomes arrive. Yahoo: Exclusivity Concerns

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.